- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 464921, 8 pages
Oxidation of Marine Omega-3 Supplements and Human Health
1Liggins Institute, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
2Gravida: National Centre for Growth and Development, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Received 15 February 2013; Revised 4 April 2013; Accepted 9 April 2013
Academic Editor: Gabriella Calviello
Copyright © 2013 Benjamin B. Albert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Marine omega-3 rich oils are used by more than a third of American adults for a wide range of purported benefits including prevention of cardiovascular disease. These oils are highly prone to oxidation to lipid peroxides and other secondary oxidation products. Oxidized oils may have altered biological activity making them ineffective or harmful, though there is also evidence that some beneficial effects of marine oils could be mediated through lipid peroxides. To date, human clinical trials have not reported the oxidative status of the trial oil. This makes it impossible to understand the importance of oxidation to efficacy or harm. However, animal studies show that oxidized lipid products can cause harm. Oxidation of trial oils may be responsible for the conflicting omega-3 trial literature, including the prevention of cardiovascular disease. The oxidative state of an oil can be simply determined by the peroxide value and anisidine value assays. We recommend that all clinical trials investigating omega-3 harms or benefits report the results of these assays; this will enable better understanding of the benefits and harms of omega-3 and the clinical importance of oxidized supplements.
Marine omega-3 rich oils (marine oils) are the most popular supplements in the United States; after a rapid rise in popularity, they are now used by more than a third of American adults [1, 2]. Marine oils (derived from fish, krill, shellfish, calamari, or algae) differ from terrestrial plant sources of omega-3 fatty acids such as flaxseed as they contain the long chain polyunsaturated fatty acids (LC-PUFAs), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). They show promise particularly in the prevention of cardiovascular disease , the treatment of inflammatory disease , improving early life neurodevelopment, preventing cognitive decline , and potential benefits to metabolism . However, it is important to understand that unlike most pharmacological and neutraceutical interventions, these oils are highly susceptible to oxidation. There has been concern about the safety of oxidized fish oil since the 1950s , and although there is evidence that over-the-counter supplements are frequently oxidized, this has had no impact on the requirements for storage and labelling or on the design of human clinical trials. No human efficacy trials have reported the oxidative state of the trial oil which would question the validity of the results and conclusions of these trials. It is currently unclear to what degree the oxidation of fish oil influences its efficacy or harm in humans. This commentary discusses these issues and outlines the implications for interpreting the literature and improving clinical trial design.
2. How Stable Are Marine Omega-3 Supplements?
n-3 LC-PUFAs are chemically unstable, so that marine oils rapidly oxidize during storage to a complex chemical soup of lipid peroxides, secondary oxidation products, and diminishing concentrations of unoxidized fatty acids. As a result, the composition of a fish oil supplement cannot be simply inferred from the labelled EPA and DHA concentrations.
n-3 LC-PUFAs are highly prone to oxidation due to their large number of double bonds and their position within the fatty acid chain [8, 9]. This makes them prone to oxidation because bisallylic carbons, those between two double-bonded carbon atoms, have a low activation energy for hydrogen loss and free radical formation . n-3 LC-PUFAs have more of these vulnerable bisallylic carbons (EPA : 4, DHA : 5) than the short n-3 PUFA (α-linolenic acid : 2) or n-6 PUFAS (arachidonic acid : 3) while the monounsaturated fatty acids and saturated fatty acids have none. In the presence of various initiators, a lipid radical is formed starting an expansive chain reaction which creates lipid peroxides and more radicals from unoxidized PUFAs. A complex array of different peroxide molecules arises depending on the position of the oxidized carbon, and after undergoing cis-trans isomerisation and a shift of double bonds, conjugated dienes and trienes are produced which have different polarity and shape to the original fatty acid . A potentially important class of n-3 peroxidation products, the prostaglandin-like F3-isoprostanes and F4-neuroprostanes are formed from EPA and DHA, respectively . Thus, the primary oxidation products of n-3 LC-PUFAs are chemically different from unoxidized n-3 LC-PUFAs and may have different biological properties.
Lipid peroxides are unstable and further degrade to form secondary oxidation products including aldehydes such as 4-hydroxyhexenal (HHE) and malondialdehyde (MDA) . As the oil oxidizes over time, there is an initial exponential increase in the concentration of lipid peroxides. These later degrade and the concentration of potentially harmful secondary oxidation products increases as the lipid peroxides decrease.
The rate of lipid peroxidation is influenced by light, heat, and oxygen concentration even at normal room conditions. Moreover, even oil stored in the dark at 4°C may oxidize unacceptably within a month of storage . Added antioxidants reduce but do not prevent oxidation . The tendency of n-3 LC-PUFAs to oxidize under light is also influenced by the presence of impurities such as protein or heavy metals and its conjugate; phospholipids are more prone to oxidation than triglycerides . Because peroxidation is an accelerating chain reaction, small concentrations of peroxides in the source oil, or exposure to oxidising conditions during processing could have a large effect on the rate of oxidation. In addition, deodourisation to remove fishy odour often involves high temperature which may accelerate secondary oxidation. Significant peroxidation is highly likely to occur in over-the-counter supplements which are commonly kept at room temperature both in retail shops and in the home.
Oil in an omega-3 supplement may differ substantially from the oil in fresh fish depending on its age, heat and light exposure. As a result, these supplements should be viewed as a complex mix of EPA, DHA, other fatty acids, additives, and an unspecified concentration of potentially toxic lipid peroxides and secondary oxidation products.
3. Can Oxidation Be Easily Quantified and Reported?
Measurement of specific lipid peroxide species and secondary oxidation products requires gas-chromatography mass-spectrometry [14–17] or other chromatographic techniques  which are expensive and require significant technical expertise. However, the oxidative status of supplemental oils can be easily estimated using the peroxide value (PV) and anisidine value (AV) assays. While these are nonspecific, they are repeatable, simple, and cost effective, and guidelines exist for recommended maximum levels in marine omega-3 supplements. The peroxide value (PV) is a simple titration enabling quantification of the concentration of peroxide groups in oil  while the anisidine value (AV) is a colorimetric test which enables estimation of the concentration of secondary oxidation products. Both measurements are required to estimate total oxidation (TOTOX = 2 PV + AV).
A number of organisations have endorsed maximum recommended levels of oxidation in supplements [19–22]; though due to the paucity of human evidence, these are based on palatability and not the effect on human health . Clearly, this implies a need for evidence-based guidelines. The simplest way to improve the knowledge base would be for clinical trials to report the oxidative status of their trial oils, so that benefits and harms could be associated with the oxidative state.
4. Are Over-the-Counter Marine Omega-3 Supplements Significantly Oxidized?
The oxidative states of retail oils are not routinely labelled and it is surprising that there has not been more formal evaluation of the oxidative stability of marketed omega-3 supplements. When over-the-counter supplements have been investigated, the frequency of excess oxidation [19–22] was highly variable but not uncommon, affecting between 11%–62% of products [23–27]. Thus, consuming purchased supplements entails risk of exposure to unacceptably oxidized oil, and it is likely that the omega-3 supplements used in many clinical trials have also been significantly oxidized. Understanding the effects of oxidized omega-3 LC-PUFAs on health is thus important both for the vast number of supplement consumers and for scientists and clinicians interpreting the medical literature.
5. Are Oxidized Omega-3 Oils Efficacious?
To our knowledge, no clinical trial investigating the efficacy of omega-3 in humans has reported the oxidative state of the trial oil or compared oxidized and nonoxidized oils. The relative efficacy of highly oxidized and nonoxidized oil cannot be inferred. However, it is likely that there is a difference.
The mechanisms of action of omega-3 are not fully understood, but there are multiple interacting mechanisms including acting as a ligand for intracellular and extracellular receptors, competition for metabolism by enzymes, structural roles in cell membrane, and stearic interference with ion channels. For illustration, triglyceride lowering is mediated by interaction with sterol receptor binding protein 1-c (SREBP1-c) and the peroxisome proliferator activated receptor alpha (PPAR-α) . Anti-inflammatory, hypotensive, and antiplatelet effects may be mediated by competition with arachidonic acid for synthesis of eicosanoids by the enzyme cyclooxygenase . Antiarrhythmic effects are in part due to stearic interference with ion channels . Insulin sensitisation is partly mediated by interaction with PPAR-γ an intracellular transcription factor  and binding to the recently discovered G-protein linked receptor GPR120 on the cell surface . Omega-3 fatty acids may also have anti-oxidant effects  and influence cell membrane fluidity .
As lipid peroxides have different shape, polarity, and reactivity to their parent fatty acid, it is likely that they will be ineffective through some if not all of these mechanisms. Because these mechanisms are diverse, the effect of oxidized supplements may be divergent, some beneficial effects may be lost but not others; lipid peroxides may even have their own unique functions.
Surprisingly, there are no specific clinical trials investigating the effects of oxidation on the efficacy of marine n-3. However, in a clinical trial of fish oil supplementation with and without the anti-oxidant vitamin E, triglycerides decreased significantly more in the vitamin E group . Increased efficacy with vitamin E is most likely due to prevention of oxidation of the oil either prior to consumption or in vivo. Interestingly, in a study of liver tissue in culture, oxidized EPA inhibited the inflammatory NF-κB pathway . This may be mediated by n-3 derived isoprostanes, as these peroxides have been shown to be biologically active, inhibiting macrophage NF-κB activation in tissue culture ; and affecting vascular and platelet function . It is not yet clear whether these effects are important in vivo; however, they provide evidence for a divergence of effects when n-3 LC-PUFAs are oxidized. Clearly, the effect of oxidation on efficacy of omega-3 requires more investigation; at minimum, the oxidative state of supplements used in clinical trials must be reported. Further, detailed studies are also required to establish both the bioavailability of individual oxidized lipid species and to provide greater insights into their biological functioning.
6. Are Oxidized Omega-3 Supplements Harmful?
There are insufficient interventional human studies that examine potential biological functions of oxidized marine n-3; however, there is evidence that lipid peroxidation is involved in human disease. In addition, animal studies show that oxidized lipids may cause organ damage, inflammation, carcinogenesis, and advanced atherosclerosis. These deleterious effects cannot be ignored, particularly when marine n-3 is taken during vulnerable stages of life such as pregnancy, early childhood, and old age and for long periods of time.
Lipid peroxides are absorbed through the gut and incorporated into chylomicrons , LDL , and VLDL . Their active transport in LDL particles and particularly subsequent oxidation of LDL may be important in atherogenesis [11, 39]. Lipid peroxides also partially decompose to secondary oxidation products in the gut which are absorbed .
Lipid peroxides hasten oxidation of other fatty acids to create further lipid peroxides in an expansive chain reaction. We speculate that ingested omega-3 peroxides could lead to lipid membrane peroxidation, cell damage, and oxidative stress, which are known to be mechanisms of disease. Endogenous membrane lipid peroxidation results in altered membrane fluidity, transport, and cell signalling  which also may be an important disease mechanism. For example, acute severe lipid and protein peroxidation has been shown to be the cause of death when, despite appropriate treatment, people die from organophosphate poisoning . Chronic lipid peroxidation may be a mechanism in carcinogenesis  and in the pathogenesis of Alzheimer’s disease where the secondary oxidation product 4-hydroxynonenal (HNE) appears to have a role in both the formation of neurofibrillary tangles and neurotoxicity . Oxidative stress further activates the NF-κB pathway and increases production of proinflammatory cytokines . Chronic low grade inflammation is involved in degenerative disease including atherogenesis  and the generation of insulin resistance in the metabolic syndrome .
Animal studies provide clear evidence that oxidized lipids are harmful, though typically using higher doses of oil than humans consume or administering oxidation products in nonphysiological ways . Chronic feeding of oxidized PUFAs to rats led to growth retardation, intestinal irritation, liver and kidney enlargement, haemolytic anaemia, decreased vitamin E, increased lipid peroxides and inflammatory changes in the liver, cardiomyopathy, and potentially malignant colon cell proliferation . A major secondary oxidation product of omega-3 oils is the aldehyde HHE. HHE when injected into the peritoneum causes necrotising peritonitis and when injected intravenously causes liver damage. It is chemically similar to the better studied omega-6 oxidation product HNE which is known to be highly toxic and causes DNA damage [11, 42].
There is increasing evidence that in vivo oxidation of LDL has a role in atherogenesis . Unmodified LDL cannot induce foam cell formation; however, after oxidative modification it can be recognised by the scavenger receptor of macrophages and is rapidly absorbed [9, 48]. Given that ingested peroxides are transported in LDL , it is possible that they could have a role in enhancing LDL oxidation and atherogenesis. This is supported by a study in rabbits where addition of fish oil to a high cholesterol diet led to rapid atherosclerosis . We speculate that if this is due to oxidation of LDL, ingested oxidized marine n-3 could be atherogenic in humans. This could contribute to the disappointing results in primary and secondary cardiovascular prevention trials  and requires further investigation.
Consuming marine oil leads to increased plasma  and urinary  MDA in humans and mice, due to both absorption of peroxidized oil and in vivo oxidation with subsequent degradation of peroxides . This is only partially reduced by addition of antioxidants [51–53]. MDA induces transition, transversion, and frame shift DNA mutations . It has been shown to cause thyroid tumours when fed to rats and skin cancer with topical application . The little evidence in humans is unclear; however, women with breast cancer have higher concentrations of MDA-DNA adducts in their normal breast tissue than controls, consistent with MDA exposure increasing risk .
One human-randomized placebo-controlled trial has examined the effects of oxidized versus nonoxidized oil over 7 weeks . No difference was found in markers of in vivo lipid peroxidation (urinary 8-isoFGF2α, plasma HHE and HNE), markers of antioxidant activity, C-reactive protein, or liver function tests. This suggests that oxidized marine n-3 may not be associated with acute oxidative toxicity. However, this is not reassuring as the study was short and did not assess important pathological markers associated with atherosclerosis such as oxidized LDL or carotid artery intimal thickness. Further, there was no assessment of specific inflammatory markers such as prostaglandins and cytokines or of markers of DNA damage. Thus, the risks of atherosclerosis, DNA damage, malignancy, and inflammation especially at tissue level remain open. If low grade, chronic peroxide, aldehyde, or MDA exposure is important in disease it may require long periods of followup to identify an effect. Some pathological effects such as tissue level inflammation may be difficult to detect without invasive methods such as muscle, liver, or adipose tissue biopsy.
In summary, given the paucity of specific evidence, it is currently impossible to know whether marine oils, some of the world’s most popular supplements, are safe after oxidation. The effects of oxidation on the biological effects of these oils may be complex, there could be both beneficial [10, 34, 35] and harmful effects. Thus, long-term safety studies of marine oil are required, looking at appropriate disease outcomes and surrogates and relating these to the oxidative state.
7. Why Is the Omega-3 Supplementation Literature Conflicting?
The omega-3 supplementation literature is highly conflicting, especially in the area most heavily researched, the effect on cardiovascular disease. Oxidation may be a major cause of these conflicting results; however, it has never been reported in these trials.
Epidemiological studies link higher dietary [58–64] or plasma n-3 LC-PUFAs [63, 65–67] to lower risk of diabetes and cardiovascular disease. Furthermore, supplementation with encapsulated fish oil or fortified foods improves a wide range of cardiovascular risk factors including lipid profile [68–73], blood pressure [69, 74, 75], heart rate  and variability [77, 78], platelet aggregation [79, 80], endothelial function , and atherosclerotic plaque stability . After myocardial infarction, fish oil reduces sudden cardiovascular death probably due to an antiarrhythmic effect [29, 83–85]. Systematic reviews of minor outcomes such as blood pressure [86, 87] and plasma triglycerides  are overall positive; however, individual studies are mixed. Moreover, despite the abundant evidence for improvement of cardiovascular risk factors, the results of primary and secondary prevention trials have been conflicting [89–91], and a recent systematic review found no overall effect of marine oil supplementation on the risk of all-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke . In explaining the conflicting effects of marine oil on health, authors have overlooked oxidized supplement as an explanation. Alternative explanations include a true lack of efficacy, obscuration of benefit by other cotreatments that improve cardiovascular risk such as statins, aspirin and beta-blockers , high background fish intake in some populations , and underpowered studies. However, it must be recognised that the oxidative status of the trial oil could also explain these disappointing results. If oxidized oils are less efficacious, or if they cause harm, for example, by advancing atherosclerosis then provided some studies used oxidized supplements, these results would be expected. We are currently in danger of concluding that marine n-3 supplements are ineffective in the prevention of cardiovascular disease, before they have been adequately investigated.
8. What Are the Implications for Interpretation of the Literature and Future Clinical Trials?
To assess the degree to which the importance of oxidation of marine oil is understood, we identified all human clinical trials published in 2012 using Pubmed. Of 107 reports, only one study investigating short-term harm reported the oxidative state of the trial oil (previously described) . This strongly suggests that the instability of marine oil is generally unrecognized or not considered important.
It is currently impossible to determine how oxidation affects the efficacy or potential harms of marine oil. This makes interpretation of the clinical trial literature problematic. If the oxidative state of marine oils may affect efficacy or harm, then physicians should recommend, and consumers select, a supplement with the same oxidative state as the oils used in clinical trials that have shown benefit and safety. This is currently impossible because although over-the-counter-supplements are frequently oxidized [23–27]; the oxidative state of trial oils and retail supplements remain unreported.
That marine oils have beneficial effects on many indices such as plasma triglycerides, blood pressure, inflammation, and insulin sensitivity (in rodents) is not in question. The purpose of this commentary is to highlight the limited knowledge about the importance of oxidation to these effects. For example, some in vitro and animal studies have stored oil under conditions likely to prevent oxidation such as under nitrogen or at very low temperature [94–97]. This confirms for example, that unoxidized marine oil prevents insulin resistance in the rat . However, whether oxidized oil has the same effect is unknown. In contrast, emerging evidence has shown that some in vitro anti-inflammatory effects are solely mediated by oxidized oil, but the clinical relevance of this is unclear.
Future safety and efficacy trials, particularly in humans, should report the oxidative state of the marine oil. This could most easily be done by reporting the peroxide, anisidine, and TOTOX values. Even established benefits of marine oil need to be reinvestigated with provision of this information. In parallel, there should be a move to labelling marine oil supplements with these same oxidative indices and a production and storage chain that minimizes oxidation prior to purchase. Only then can we generalise efficacy and safety trial data to the available omega-3 supplements and provide informed recommendations to patients and consumers.
Conflict of Interests
The authors have no conflict of interests to declare.
The authors gratefully acknowledge the Sir Graeme and Lady Douglas Research Trust for generous support of Dr Albert’s research fellowship. The authors further thank Dr José Derraik for assistance in formatting the paper.
- P. M. Barnes, B. Bloom, and R. L. Nahin, Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 2008.
- P. M. Barnes, E. Powell-Griner, K. McFann, and R. L. Nahin, “Complementary and alternative medicine use among adults: United States, 2002,” Advance Data, no. 343, pp. 1–19, 2004.
- P. C. Calder, “n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored,” Clinical Science, vol. 107, no. 1, pp. 1–11, 2004.
- P. C. Calder, “Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?” British Journal of Clinical Pharmacology, vol. 75, pp. 645–662, 2013.
- J. E. Karr, J. E. Alexander, and R. G. Winningham, “Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan: a review,” Nutritional Neuroscience, vol. 14, no. 5, pp. 216–225, 2011.
- N. S. Kalupahana, K. J. Claycombe, and N. Moustaid-Moussa, “(n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights,” Advances in Nutrition, vol. 2, pp. 304–316, 2011.
- N. Matsuo, “Studies on the toxicity of fish oil,” The Journal of Biochemistry, vol. 41, pp. 481–487, 1954.
- F. Shahidi and Y. Zhong, “Lipid oxidation and improving the oxidative stability,” Chemical Society Reviews, vol. 39, no. 11, pp. 4067–4079, 2010.
- I. F. F. Benzie, “Lipid peroxidation: a review of causes, consequences, measurement and dietary influences,” International Journal of Food Sciences and Nutrition, vol. 47, no. 3, pp. 233–261, 1996.
- A. Barden, E. Mas, P. Henry et al., “The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function,” Free Radical Research, vol. 45, no. 4, pp. 469–476, 2011.
- H. Esterbauer, “Cytotoxicity and genotoxicity of lipid-oxidation products,” American Journal of Clinical Nutrition, vol. 57, no. 5, pp. 779S–785S, 1993.
- C. S. Pak, Stability and Quality of Fish Oil During Typical Domestic Application, United Nations University, Reykjavik, Iceland, 2005, http://www.unuftp.is/static/fellows/document/pak05prf.pdf.
- P. C. Zuta, B. K. Simpson, X. Zhao, and L. Leclerc, “The effect of α-tocopherol on the oxidation of mackerel oil,” Food Chemistry, vol. 100, no. 2, pp. 800–807, 2007.
- D. W. Thomas, F. J. G. M. van Kuijk, E. A. Dratz, and R. J. Stephens, “Quantitative determination of hydroxy fatty acids as an indicator of in vivo lipid peroxidation: gas chromatography-mass spectrometry methods,” Analytical Biochemistry, vol. 198, no. 1, pp. 104–111, 1991.
- H. C. Yee, H. J. Helbock, D. W. Chyu, and B. N. Ames, “Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry,” Analytical Biochemistry, vol. 220, no. 2, pp. 391–396, 1994.
- X. P. Luo, M. Yazdanpanah, N. Bhooi, and D. C. Lehotay, “Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry,” Analytical Biochemistry, vol. 228, no. 2, pp. 294–298, 1995.
- A. E. Barden, K. D. Croft, T. Durand, A. Guy, M. J. Mueller, and T. A. Mori, “Flaxseed oil supplementation increases plasma F1-phytoprostanes in healthy men,” Journal of Nutrition, vol. 139, no. 10, pp. 1890–1895, 2009.
- European Pharmacopoeia Commission, “European Pharmacopoeia 5.0,” Council of Europe, 2005, http://lib.njutcm.edu.cn/yaodian/ep/EP5.0/index.html.
- EFSA Panel on Biological Hazards (BIOHAZ), “Scientific opinion on fish oil for human consumption. Food hygiene, including rancidity,” EFSA Journal, vol. 8, no. 10, p. 48, 2010.
- Global Organization for EPA and DHA Omega-3, “GOED Voluntary Monograph (v.4),” 2012, http://www.goedomega3.com/images/stories/files/goedmonograph.pdf.
- Health Canada, “Monograph: Fish Oil,” 2009, http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=88&lang=eng.
- USA Council for Responsible Nutrition, “Voluntary Monograph: Omega-3 DHA, Omega-3 EPA, Omega-3 DHA & EPA,” 2006, http://www.crnusa.org/pdfs/O3FINALMONOGRAPHdoc.pdf.
- B. L. Halvorsen and R. Blomhoff, “Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements,” Food and Nutrition Research, vol. 55, no. 1, 2011.
- W. Kolanowski, “Omega-3 LC PUFA contents and oxidative stability of encapsulated fish oil dietary supplements,” International Journal of Food Properties, vol. 13, no. 3, pp. 498–511, 2010.
- “Something fishy? Omega-3 supplements test,” Consumer, vol. 469, pp. 12–15, 2007.
- C. Fierens and J. Corthout, “Omega-3 fatty acid preparations—a comparative study,” Journal de Pharmacie de Belgique, vol. 62, no. 4, pp. 115–119, 2007.
- C. M. Fantoni, A. P. Cuccio, and D. Barrera-Arellano, “Brazilian encapsulated fish oils: oxidative stability and fatty acid composition,” Journal of the American Oil Chemists' Society, vol. 73, no. 2, pp. 251–253, 1996.
- M. H. Davidson, “Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids,” American Journal of Cardiology, vol. 98, no. 4, pp. 27–33, 2006.
- R. De Caterina, R. Madonna, R. Zucchi, and M. T. La Rovere, “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside,” American Heart Journal, vol. 146, no. 3, pp. 420–430, 2003.
- D. Y. Oh, S. Talukdar, E. J. Bae et al., “GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects,” Cell, vol. 142, no. 5, pp. 687–698, 2010.
- D. Richard, K. Kefi, U. Barbe, P. Bausero, and F. Visioli, “Polyunsaturated fatty acids as antioxidants,” Pharmacological Research, vol. 57, no. 6, pp. 451–455, 2008.
- S. E. Feller, K. Gawrisch, and A. D. MacKerell Jr., “Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties,” Journal of the American Chemical Society, vol. 124, no. 2, pp. 318–326, 2002.
- O. Haglund, R. Luostarinen, R. Wallin, L. Wibell, and T. Saldeen, “The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E,” Journal of Nutrition, vol. 121, no. 2, pp. 165–169, 1991.
- A. Mishra, A. Chaudhary, and S. Sethi, “Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 9, pp. 1621–1627, 2004.
- J. D. Brooks, E. S. Musiek, T. R. Koestner, et al., “The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation,” Journal of Neurochemistry, vol. 119, no. 3, pp. 604–616, 2011.
- I. Staprans, J. H. Rapp, X. M. Pan, K. Y. Kim, and K. R. Feingold, “Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum,” Arteriosclerosis and Thrombosis, vol. 14, no. 12, pp. 1900–1905, 1994.
- M. Ahotupa, J. P. Suomela, T. Vuorimaa, and T. Vasankari, “Lipoprotein-specific transport of circulating lipid peroxides,” Annals of Medicine, vol. 42, no. 7, pp. 521–529, 2010.
- J. P. Suomela, M. Ahotupa, O. Sjövall, J. P. Kurvinen, and H. Kallio, “Diet and lipoprotein oxidation: analysis of oxidized triacylglycerols in pig lipoproteins,” Lipids, vol. 39, no. 7, pp. 639–647, 2004.
- J. T. Salonen, S. Ylä-Herttuala, R. Yamamoto et al., “Autoantibody against oxidised LDL and progression of carotid atherosclerosis,” The Lancet, vol. 339, no. 8798, pp. 883–887, 1992.
- K. Kanazawa and H. Ashida, “Dietary hydroperoxides of linoleic acid decompose to aldehydes in stomach before being absorbed into the body,” Biochimica et Biophysica Acta, vol. 1393, no. 2-3, pp. 349–361, 1998.
- J. Vidyasagar, N. Karunakar, M. S. Reddy, K. Rajnaranyana, T. Surender, and D. R. Krishna, “Oxidative stress and antioxidant status in acute organophosphorous insecticide poisoning,” Indian Journal of Pharmacology, vol. 36, no. 2, pp. 76–79, 2004.
- H. Bartsch and J. Nair, “Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair,” Langenbeck's Archives of Surgery, vol. 391, no. 5, pp. 499–510, 2006.
- L. M. Sayre, D. A. Zelasko, P. L. R. Harris, G. Perry, R. G. Salomon, and M. A. Smith, “4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997.
- R. van den Berg, G. R. M. M. Haenen, H. van den Berg, and A. Bast, “Transcription factor NF-κB as a potential biomarker for oxidative stress,” British Journal of Nutrition, vol. 86, no. 1, pp. S121–S127, 2001.
- P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002.
- A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000.
- G. M. Chisolm and D. Steinberg, “The oxidative modification hypothesis of atherogenesis: an overview,” Free Radical Biology and Medicine, vol. 28, no. 12, pp. 1815–1826, 2000.
- J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 1, pp. 333–337, 1979.
- J. Thiery and D. Seidel, “Fish oil feeding results in an enhancement of cholesterol-induced atherosclerosis in rabbits,” Atherosclerosis, vol. 63, no. 1, pp. 53–56, 1987.
- B. Rauch, R. Schiele, S. Schneider et al., “OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction,” Circulation, vol. 122, no. 21, pp. 2152–2159, 2010.
- L. A. Piche, H. H. Draper, and P. D. Cole, “Malondialdehyde excretion by subjects consuming cod liver oil vs a concentrate of n-3 fatty acids,” Lipids, vol. 23, no. 4, pp. 370–371, 1988.
- S. H. Cho and Y. S. Choi, “Lipid peroxidation and antioxidant status is affected by different vitamin E levels when feeding fish oil,” Lipids, vol. 29, no. 1, pp. 47–52, 1994.
- M. J. Gonzalez, J. I. Gray, R. A. Schemmel, L. Dugan, and C. W. Welsch, “Lipid peroxidation products are elevated in fish oil diets even in the presence of added antioxidants,” Journal of Nutrition, vol. 122, no. 11, pp. 2190–2195, 1992.
- A. K. Basu and L. J. Marnett, “Unequivocal demonstration that malondialdehyde is a mutagen,” Carcinogenesis, vol. 4, no. 3, pp. 331–333, 1983.
- L. J. Marnett, “Lipid peroxidation—DNA damage by malondialdehyde,” Mutation Research, vol. 424, no. 1-2, pp. 83–95, 1999.
- M. Wang, K. Dhingra, W. N. Hittelman, J. G. Liehr, M. de Andrade, and D. Li, “Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 9, pp. 705–710, 1996.
- I. Ottestad, G. Vogt, K. Retterstøl, et al., “Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial,” British Journal of Nutrition, vol. 108, no. 2, pp. 315–326, 2012.
- R. Villegas, Y. B. Xiang, T. Elasy et al., “Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women,” American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 543–551, 2011.
- H. Iso, M. Kobayashi, J. Ishihara et al., “Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) study cohort I,” Circulation, vol. 113, no. 2, pp. 195–202, 2006.
- A. Sekikawa, H. Ueshima, T. Kadowaki et al., “Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-world war II birth cohort,” American Journal of Epidemiology, vol. 165, no. 6, pp. 617–624, 2007.
- D. Kromhout, E. B. Bosschieter, and C. de Lezenne Coulander, “The inverse relation between fish consumption and 20-year mortality from coronary heart disease,” The New England Journal of Medicine, vol. 312, no. 19, pp. 1205–1209, 1985.
- H. O. Bang, J. Dyerberg, and A. B. Nielsen, “Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos,” The Lancet, vol. 1, no. 7710, pp. 1143–1145, 1971.
- C. M. Albert, H. Campos, M. J. Stampfer et al., “Blood levels of long-chain n-3 fatty acids and the risk of sudden death,” The New England Journal of Medicine, vol. 346, no. 15, pp. 1113–1118, 2002.
- M. L. Daviglus, J. Stamler, A. J. Orencia et al., “Fish consumption and the 30-year risk of fatal myocardial infarction,” The New England Journal of Medicine, vol. 336, no. 15, pp. 1046–1053, 1997.
- L. Djoussé, M. L. Biggs, R. N. Lemaitre, et al., “Plasma omega-3 fatty acids and incident diabetes in older adults,” The American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 527–533, 2011.
- J. C. Liu, S. M. Conklin, S. B. Manuck, J. K. Yao, and M. F. Muldoon, “Long-chain omega-3 fatty acids and blood pressure,” American Journal of Hypertension, vol. 24, no. 10, pp. 1121–1126, 2011.
- D. S. Siscovick, T. E. Raghunathan, I. King et al., “Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest,” Journal of the American Medical Association, vol. 274, no. 17, pp. 1363–1367, 1995.
- W. S. Harris, “n-3 fatty acids and lipoproteins: comparison of results from human and animal studies,” Lipids, vol. 31, no. 3, pp. 243–252, 1996.
- M. Kestin, P. Clifton, G. B. Belling, and P. J. Nestel, “n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants,” American Journal of Clinical Nutrition, vol. 51, no. 6, pp. 1028–1034, 1990.
- C. Dawczynski, L. Martin, A. Wagner, and G. Jahreis, “N-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study,” Clinical Nutrition, vol. 29, no. 5, pp. 592–599, 2010.
- M. Svensson, E. B. Schmidt, K. A. Jørgensen, and J. H. Christensen, “The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2918–2924, 2008.
- C. von Schacky, “A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels,” Vascular Health and Risk Management, vol. 2, no. 3, pp. 251–262, 2006.
- P. J. Nestel, “Fish oil attenuates the cholesterol induced rise in lipoprotein cholesterol,” American Journal of Clinical Nutrition, vol. 43, no. 5, pp. 752–757, 1986.
- J. Dyerberg, J. H. Christensen, D. Eskesen, A. Astrup, and S. Stender, “Trans, and n-3 polyunsaturated fatty acids and vascular function—a yin yang situation?” Atherosclerosis Supplements, vol. 7, no. 2, pp. 33–35, 2006.
- G. K. Paschos, F. Magkos, D. B. Panagiotakos, V. Votteas, and A. Zampelas, “Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients,” European Journal of Clinical Nutrition, vol. 61, no. 10, pp. 1201–1206, 2007.
- D. Mozaffarian, A. Geelen, I. A. Brouwer, J. M. Geleijnse, P. L. Zock, and M. B. Katan, “Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials,” Circulation, vol. 112, no. 13, pp. 1945–1952, 2005.
- J. H. Christensen, P. Gustenhoff, E. Korup et al., “Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial,” British Medical Journal, vol. 312, no. 7032, pp. 677–678, 1996.
- J. H. Christensen, M. S. Christensen, J. Dyerberg, and E. B. Schmidt, “Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids,” American Journal of Clinical Nutrition, vol. 70, no. 3, pp. 331–337, 1999.
- T. A. Mori, L. J. Beilin, V. Burke, J. Morris, and J. Ritchie, “Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 2, pp. 279–286, 1997.
- L. Axelrod, J. Camuso, E. Williams, K. Kleinman, E. Briones, and D. Schoenfeld, “Effects of a small quantity of ω-3 fatty acids on cardiovascular risk factors in NIDDM: a randomized, prospective, double-blind, controlled study,” Diabetes Care, vol. 17, no. 1, pp. 37–44, 1994.
- F. Khan, K. Elherik, C. Bolton-Smith et al., “The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects,” Cardiovascular Research, vol. 59, no. 4, pp. 955–962, 2003.
- F. Thies, J. M. C. Garry, P. Yaqoob et al., “Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial,” The Lancet, vol. 361, no. 9356, pp. 477–485, 2003.
- R. Marchioli, F. Barzi, E. Bomba et al., “Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione,” Circulation, vol. 105, no. 16, pp. 1897–1903, 2002.
- M. L. Burr, A. M. Fehily, J. F. Gilbert et al., “Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART),” The Lancet, vol. 2, no. 8666, pp. 757–761, 1989.
- R. B. Singh, M. A. Niaz, J. P. Sharma, R. Kumar, V. Rastogi, and M. Moshiri, “Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival—4,” Cardiovascular Drugs and Therapy, vol. 11, no. 3, pp. 485–491, 1997.
- J. M. Geleijnse, E. J. Giltay, D. E. Grobbee, A. R. T. Donders, and F. J. Kok, “Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials,” Journal of Hypertension, vol. 20, no. 8, pp. 1493–1499, 2002.
- M. C. Morris, F. Sacks, and B. Rosner, “Does fish oil lower blood pressure? A meta-analysis of controlled trials,” Circulation, vol. 88, no. 2, pp. 523–533, 1993.
- E. M. Balk, A. H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau, “Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review,” Atherosclerosis, vol. 189, no. 1, pp. 19–30, 2006.
- J. Bosch, H. C. Gerstein, G. R. Dagenais, et al., “n-3 fatty acids and cardiovascular outcomes in patients with dysglycaemia,” The New England Journal of Medicine, vol. 367, no. 4, pp. 309–318, 2012.
- M. Yokoyama, H. Origasa, M. Matsuzaki et al., “Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis,” The Lancet, vol. 369, no. 9567, pp. 1090–1098, 2007.
- C. Wang, W. S. Harris, M. Chung et al., “n-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review,” American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 5–17, 2006.
- E. C. Rizos, E. E. Ntzani, E. Bika, M. S. Kostapanos, and M. S. Elisaf, “Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 308, no. 10, pp. 1024–1033, 2012.
- Y. Nakamura, H. Ueshima, T. Okamura et al., “Association between fish consumption and all-cause and cause-specific mortality in Japan: NIPPON DATA80, 1980–99,” American Journal of Medicine, vol. 118, no. 3, pp. 239–245, 2005.
- M. Awada, A. Meynier, C. O. Soulage, et al., “n-3 PUFA added to high-fat diets affect differently adiposity and inflammation when carried by phospholipids or triacylglycerols in mice,” Nutrition & Metabolism, vol. 10, no. 1, pp. 1–14, 2013.
- Ghafoorunissa, A. Ibrahim, L. Rajkumar, and V. Acharya, “Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats,” Journal of Nutrition, vol. 135, no. 11, pp. 2634–2638, 2005.
- Y. B. Lombardo, G. Hein, and A. Chicco, “Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity,” Lipids, vol. 42, no. 5, pp. 427–437, 2007.
- A. González-Périz, R. Horrillo, N. Ferré et al., “Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins,” The FASEB Journal, vol. 23, no. 6, pp. 1946–1957, 2009.